Biodel Inc (NASDAQ:BIOD) will present data from studies of its ultra-rapid-acting prandial/basal insulin and Glucagon Emergency Management (GEM) product candidates during the Diabetes Technology Society Conference to be held in Bethesda, MDfrom October 22 – 24, 2015.

The poster presentation (4:00 pm – 6:30 pm ET on Thursday, October 22, 2015) “Mixture of Insulin Monomers, Dimers and Hexamers Demonstrated by Sedimentation Velocity Analysis Supports Bi-Phasic Ultra-Rapid-Acting and Basal Profile of Concentrated Human Insulin Formulation BIOD-531” will detail the molecular mechanism for the unique, bi-phasic profile of BIOD-531, the Company’s proprietary, potentially best-in-class, ultra-rapid acting prandial/basal insulin candidate.

The poster presentation (4:00 pm – 6:30 pm ET on Thursday, October 22, 2015) “Biodel’s Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior Usability Compared to Marketed Glucagon Kits in Human Factors Study” will present data from formative Human Factors Studies which demonstrate clear-cut superiority of the GEM device with regard to ease-of-use, overall performance and reduction in dosing errors in comparison with the currently marketed glucagon kits.

The poster presentation (4:45 pm – 7:15 pm ET on Friday, October 23, 2015) “Pharmacokinetic and Pharmacodynamic Modeling Predict Concentrated Biphasic Insulin BIOD-531 Is Suitable for Twice or Three Times Daily Dosing with No Dose Accumulation” will present mathematical modeling of the pharmacokinetic and pharmacodynamic profiles of BIOD-531. These models predict that BIOD-531 is well suited for user-friendly dosing paradigms that are already commonly used in clinical practice. (Original Source)

Shares of Biodel closed today at $0.405, down $0.015 or -3.57%. BIOD has a 1-year high of $2 and a 1-year low of $0.39. The stock’s 50-day moving average is $0.58 and its 200-day moving average is $0.93.

On the ratings front, Wedbush analyst Liana Moussatos reiterated a Hold rating on BIOD, with a price target of $2, in a report issued on October 12. The current price target implies an upside of 387.8% from current levels. According to, Moussatos has a total average return of 13.4%, a 37.4% success rate, and is ranked #229 out of 3788 analysts.

Biodel Inc is a specialty biopharmaceutical company. The Company is focused on the development and commercialization of treatments for diabetes patients..